Drug Repurposing Against SARS-CoV2 1st Edition

Capture the forefront of COVID-19 therapeutics with Drug Repurposing Against SARS-CoV2, 1st Edition by Tabish Qidwai — an essential, evidence-driven guide for clinicians, researchers, policymakers, and graduate students tackling the pandemic’s therapeutic challenges.

From the first page, this book engages with a clear purpose: to map how existing drugs can be redirected safely and effectively against SARS-CoV-2. Drawing on an exhaustive review of preclinical studies, computational screens, and clinical trial data, Tabish Qidwai synthesizes complex pharmacology into accessible chapters that explain mechanisms of action, dosing considerations, safety profiles, and real-world outcomes. Readers will find balanced appraisals of antiviral agents, immunomodulators, and adjunctive therapies, together with pragmatic frameworks for prioritizing candidates for further study.

What sets this volume apart is its practical orientation. Each chapter closes with concise takeaways, research priorities, and regulatory and ethical insights that help translate evidence into practice. Whether you are evaluating repurposed therapeutics in a hospital setting, designing a clinical study, or shaping public health strategies, this book provides the critical context and actionable guidance you need.

Geared to a global audience — from healthcare teams in India and Europe to researchers in North America and Asia — the book speaks to the international nature of pandemic response and collaborative research. Written in a professional yet approachable tone, it balances scholarly rigor with readable clarity.

A timely, authoritative resource, Drug Repurposing Against SARS-CoV2 is a must-have reference for anyone involved in COVID-19 therapeutics. Order your copy today and equip yourself with the knowledge to inform research, treatment, and policy decisions.

Note: eBooks do not include supplementary materials such as CDs, access codes, etc.